Zydus Lifesciences Limited (ZYDUSLIFE) — Board Meeting | 9 February 2026(2 announcements)

Zydus Lifesciences' board acknowledged technical non-compliance with SEBI Listing Regulation 29 for delayed prior intimation of a November 6, 2025 board meeting on fund-raising. The company received ₹11,800 penalties each from BSE and NSE (including GST) due to a discrepancy in holiday interpretation—the company treated November 5, 2025 as a working day based on Ahmedabad bank holidays, while exchanges considered it a trading holiday. The board noted the inadvertent error with no regulatory intent, confirmed penalty payment within prescribed timelines, and committed to strengthened compliance processes.

Zydus Lifesciences Limited's board approved Q3 and nine-month unaudited results for the period ended December 31, 2025. Consolidated Q3 revenue reached ₹68,645 million with net profit of ₹10,421 million; nine-month revenue stood at ₹195,614 million with net profit of ₹37,675 million. The company completed major acquisitions including 85.6% stake in Amplitude Surgical SA (France) for €256.8 million, achieving full ownership by October 2025, and acquired Comfort Click Limited via subsidiary Alidac UK. Trading window closed February 9-11, reopening February 12, 2026.